Older adults, median around 65-70; strong male predominance
Approximately 0.04 per 100,000 per year
Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.
Clinical Presentation & Hallmark Symptoms
Presenting signs most frequently observed across clinical case series
Genomic Profiling & Defining Molecular Lesions
Critical diagnostic fusions, somatic mutations, and therapeutic targets
Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.
Standard-of-Care Treatment Protocol
Frontline and multimodal strategies established under international consensus guidelines
Tagraxofusp (CD123-directed therapy, regulatory-approved for BPDCN)
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Intensive acute-leukaemia-style or lymphoma-style induction chemotherapy
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Central nervous system prophylaxis with intrathecal chemotherapy
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Allogeneic stem cell transplant in first remission for fit patients
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Venetoclax-containing combinations in older or unfit patients
Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.
Prognosis & Disease Trajectory
Objective clinical outlook without false reassurance
Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.
Active Research, Biomarkers & Clinical Trials
Novel investigational agents, phase I/II trials, and international rare disease consortia
CD123-directed CAR-T cells, bispecific antibodies and venetoclax combinations are the leading research directions; capillary leak syndrome management with tagraxofusp is an active safety focus.
Need Help Matching to an Active Rare Cancer Trial?
ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.
Verified Specialists for Blastic Plasmacytoid Dendritic Cell Neoplasm
Dr. Naveen Pemmaraju
Hematologist-Oncologist
MD Anderson
Houston, USA
Prof. Chng Wee Joo
Senior Hematologist
NUH
Singapore, Singapore
Prof. Pier Luigi Zinzani
Hematologist
University of Bologna
Bologna, Italy
Dr. Lalit Kumar
Medical Oncologist, Former Head of Medical Oncology
AIIMS, New Delhi
New Delhi, India
Designated Cancer Centers with Dedicated Programs
NCI-Designated Comprehensive Cancer Center
World-leading rare tumor board & pediatric solid tumor protocols
NCI-Designated Comprehensive Cancer Center
Largest specialized rare cancer and sarcoma multidisciplinary program
NCI-Designated Comprehensive Cancer Center
Pioneering genomic molecular tumor boards & rare histologies
NCI-Designated Comprehensive Cancer Center
High-volume surgical oncology & rare endocrine/neuroendocrine expertise
Frequently Asked Clinical Questions
Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options
Related Rare Malignancies in Catalog
Facing a Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm?
Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.